Document is current
Any future updates will be listed below
-
Authors
Rutledge, Thomas https://orcid.org/0000-0001-6048-2302
Lafferty, Paul
Wong, Esther
Bondoc, Franchesca
Leung, Albert
-
Funding
Funding for this research was provided by:
National Institute on Drug Abuse (1R43DA053048-01)
- License Information
-
More Information
Article History
Received: 30 April 2024
Accepted: 15 December 2024
First Online: 15 January 2025
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from all individual participants included in the study.
: Dr. Rutledge declares no conflicts of interest. Paul Lafferty is the CEO of VRx Medical, the company developing the augmented reality application tested in this study. Esther Wong declares no conflicts of interest. Franchesca Bondoc declares no conflicts of interest. Dr. Albert Leung declares no conflicts of interest.
